C21 · Pharmaceuticals · China
New drugs approved for marketing after clinical trials (China registration category)
China: 248 in 2025.
- 248 Latest · China · 2025
- Annual Release cadence
- 1 Record · 1 region · 2025
Verified 26 Sep 2026 · 1 publisher · Next period 2026
The figure
One published observation so far. A chart follows as soon as a second period is published.
New drugs approved for marketing after clinical trials (China registration category)
China, 2025
Every record
1 record · 1 region · 2025. Each period links to its record: the value, the quote it was read from, and the document.
Download this data
Every file carries its provenance: the CSV has a source column per row, and the chart images print the publisher, the licence and this page's address under the drawing. Source: NHSA. Licence: CC BY 4.0.
Use and publication rights
- View, cite and link: free
Quote any number, cite this page or a single record, and link to it anywhere.
- Copy, chart and republish: free with attribution
The data is published under CC BY 4.0, commercial use included. Credit StatOrigin and the original publisher (NHSA); the chart files already carry that line.
- The source documents: the publisher's terms
Figures are facts read from the publishers' own documents. The documents themselves, their text and design, stay under each publisher's terms; follow the source links for those.
How this measure is built
- Definition
- Number of drugs in China's "new drug" registration category (innovative and improved new drugs, including TCM) approved for marketing after clinical trials, as reported by the NMPA Center for Drug Evaluation.
- Measure
- One slice of Drug approvals ( form: count, segment: new drug ) . Total number of therapeutic drugs granted regulatory marketing approval. Region and period are columns on every record, not slices.
- Limitations
- Values are shown as published; StatOrigin does not revise, fill gaps or convert currencies.
- Verification
- Each value, unit, period and place was checked against its quote before publication. See the methodology and the corrections process.
Sources · 1 document
| Document | Publisher | Published | Data points |
|---|---|---|---|
| 从“0”到“1”创新能力增强 我国新药研发热度持续攀升 | NHSA | — | 1 |
Other slices of drug approvals
- First-in-class drug approvals 9 first in class
- New active substance approvals 6 new active substance
- Innovative drug approvals 5 innovative
- Novel drug approvals 3 novel
- Pediatric medicine approvals 3 pediatric
- Rare disease medicine approvals 3 rare disease
- Approved innovative drugs designated as breakthrough therapies 2 breakthrough therapy
- Common new active substance approvals across major regulatory authorities (multi-year total) 2 cumulative · common across authorities · new active substance
- Domestic first-in-class drug approvals 2 domestic · first in class
- Domestic innovative biological product approvals 2 domestic · innovative biologic
- Domestic innovative chemical drug approvals 2 domestic · innovative chemical
- Domestic innovative drug approvals (half year) 2 domestic · innovative
Frequently asked questions
What is the latest new drugs approved for marketing after clinical trials (China registration category)?
China: 248 in 2025.
Where does this data come from?
From 1 document published by NHSA. Every figure on this page links to its record, which quotes the sentence or table row the number was read from.
How often is it updated?
Annual. The newest published period is 2025; the next release should cover 2026. A new figure appears here once the publisher releases it and it passes verification.
Can I use this data?
Yes. StatOrigin publishes it under CC BY 4.0: you may copy, chart and republish it, including commercially, with attribution to StatOrigin and to the original publisher.
Cite this page
Cite the page as a data set, or open any record to cite one figure: each record carries APA, MLA, Chicago and BibTeX forms that credit the original publisher.
StatOrigin. (2026). New drugs approved for marketing after clinical trials (China registration category) [Data set]. Retrieved September 29, 2026, from https://statorigin.org/indicators/new-drugs-approved-after-clinical-trials-cn-registration-category
"New drugs approved for marketing after clinical trials (China registration category)." StatOrigin, 2026, https://statorigin.org/indicators/new-drugs-approved-after-clinical-trials-cn-registration-category. Accessed 29 Sep. 2026.
StatOrigin. "New drugs approved for marketing after clinical trials (China registration category)." Data set, 2026. Accessed September 29, 2026. https://statorigin.org/indicators/new-drugs-approved-after-clinical-trials-cn-registration-category.
@misc{statorigin_new_drugs_approved_after_clinical_trials_cn_registration_category_2026, title = {New drugs approved for marketing after clinical trials (China registration category)}, author = {{StatOrigin}}, year = {2026}, url = {https://statorigin.org/indicators/new-drugs-approved-after-clinical-trials-cn-registration-category}, note = {Data set. Accessed 2026-09-29} }